UBS analyst Marcus Curley raised the firm’s price target on ResMed (RMD) to $325 from $285 and keeps a Buy rating on the shares. ResMed posted “solid” Q4 results, as well as “comfort” on patient starts, PAP share, resupply, and gross margin expansion, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- Resmed’s Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
- ResMed price target raised to $298 from $274 at KeyBanc
- Resmed’s CCO Bobby Ghoshal Resigns for New Role
- ResMed’s Strong Q4 Performance and Strategic Initiatives Drive Buy Rating
- Resmed Inc. Reports Strong Q4 2025 Earnings Growth